GlobeNewswire•April 26, 2019
OXNARD, Calif., April 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, has been named 2019’s Innovative Business of the Year by Oxnard Chamber of Commerce in recognition to the company’s innovative thinking for various programs, employing pioneering technology and a dedication to improving the health of the community and world.
The Oxnard Chamber of Commerce presented CURE Pharmaceutical with the “Innovative Business of the Year” award at its 69th Annual Community & Business Awards Dinner on Thursday, April 25 at 6:00 p.m. at Residence Inn by Marriott/River Ridge in Oxnard.
Mark Udell, CURE’s Chief Accounting Officer, was present to accept the award for the company and spoke briefly: “At CURE, we are dedicated to improving the health and wellness for the future. Our mission is to change the way medication is delivered in an easy-to-administer form, improving the patient experience and drug efficacy.”
The “Innovative Business of the Year” award acknowledges an Oxnard business that exhibits innovative thinking through employee benefits, programs employing technology or environmentally friendly practices.
“Oxnard is home to our business and our employees,” said Udell. “This honor recognizes our innovative work and leadership in our community, and the impact this little town can have around the world.”
For more information about the innovative work from CURE Pharmaceutical, please visit its website at www.curepharma.com.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company’s judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. On February 28, 2017, and ending on August 28, 2020, Liviakis Financial Communications, Inc. (LFC) was retained by CURE Pharmaceutical Holding Corp. (CURR) in various consulting capacities including strategic management planning, investor relations and other business development responsibilities. LFC was compensated 1,000,000 restricted common stock under rule 144. Officers and employees of LFC will buy or sell shares in CURE Pharmaceutical Holding Corp. prior, during or after this release. LFC advises CURE Pharmaceutical Holding Corp. but does not provide investment advice. LFC is not a registered investment advisor or broker-dealer. All material provided regarding CURE Pharmaceuticals Holding Corp. including, but not limited to its history, corporate status, and other developments was prepared using information approved and signed off by CURE Pharmaceutical Holding Corp. management as approved for public dissemination. Although the information contained herein is believed to be reliable, LFC makes no warranties as to the accuracy of the description of any of the content herein and accepts no liability for how readers may choose to utilize it.